Vertex Pharmaceuticals Inc VRTX shares are rising in extended trading Monday after the company announced positive interim results for one of its Phase 3 trials. Vertex Pharmaceuticals stock is trading ...

The FDA has accepted a Biologics License Application for imsidolimab to treat generalized pustular psoriasis, a rare inflammatory skin condition.

Treatments for Alzheimer disease agitation, focal segmental glomerulosclerosis, hematological malignancies, HIV-1, and obesity are under review.

Integrating Asymchem’s Payload–Linker Facility to Provide End-to-End, One-Stop Services for Drug Conjugates ...

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, ...

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript March 5, 2026 REGENXBIO Inc. misses on earnings expectations. Reported EPS is $-1.3 EPS, expectations were $-1.01. Operator: Thank you for ...

Securities fraud class action lawsuit filed -- Class Period: September 24, 2025, and October 31, 2025 -- Deadline to Seek Lead Plaintiff Status: April 13, 2026 -- Key Lawsuit Allegations: Material ...

When most people are chasing dividends and safety, they often go for defensive stocks like consumer staples. However, ...

Savara Inc. (the “Company”) (Nasdaq: SVRA ), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has received the Day 74 L ...

It started by tearing out Buddy’s dog pen, which was right outside our kitchen door. We had to put Buddy to sleep. Walking out the kitchen door and seeing his vacant pen was too much of a reminder of ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today provided an update ...